Filing Details

Accession Number:
0001209191-14-058922
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-09-19 21:03:13
Reporting Period:
2014-09-17
Filing Date:
2014-09-19
Accepted Time:
2014-09-19 21:03:13
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1463729 Receptos Inc. RCPT Pharmaceutical Preparations (2834) 264190792
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1552293 Edward S. Torres 10835 Road To The Cure, Suite 205
San Diego CA 92121
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2014-09-17 38,917 $63.67 1,328,150 No 4 S Indirect See Footnote
Common Stock Disposition 2014-09-18 91,513 $62.77 1,236,637 No 4 S Indirect See Footnote
Common Stock Disposition 2014-09-19 169,570 $62.55 1,067,067 No 4 S Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
Footnotes
  1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.00 to $64.48 per share, inclusive. The reporting person undertakes to provide to Receptos, Inc., any security holder of Receptos, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4.
  2. These shares are owned directly by Lilly Ventures Fund I LLC (the "Fund"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund. S. Edward Torres is a non-managing member of the Fund and may be deemed to beneficially own the shares. Mr. Torres disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.50 to $63.61, inclusive.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.00 to $63.40, inclusive.